Actelion Launches New PAH Drug In Vietnam; PharmaLink Gets Commercializing Rights
This article was originally published in PharmAsia News
Executive Summary
SHANGAI - Swiss biopharmaceutical company Actelion inked a deal with Singapore-based PharmaLink to introduce pulmonary arterial hypertension treatment Tracleer (bosentan) to Vietnam, the two companies announced July 10 in Ho Chi Minh City
You may also be interested in...
Actelion Adds to PAH Franchise with IV drug from GeneraMedix
Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.
Actelion Adds to PAH Franchise with IV drug from GeneraMedix
Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.
Actelion Secures Rights to Nippon Shinyaku’s Hypertension Drug
TOKYO - Switzerland-based biopharma Actelion, has signed a deal this week with Kyoto-based pharma Nippon Shinyaku Co. to license the Japanese company's prostaglandin I-2 receptor agonist NS-304, designed to treat pulmonary arterial hypertension